- Antibody Drug Conjugates (ADCs), which combine the targeting ability of monoclonal antibodies with the cancer-killing potency of cytotoxic drugs, are becoming essential components of precision oncology treatment in Europe due to their targeted mechanism, minimized systemic toxicity, and growing adoption in hematologic and solid tumor therapies
- The rising demand for ADCs is primarily driven by the increasing cancer burden across European countries, a shift toward personalized medicine, and growing awareness and acceptance of novel biologic therapies among healthcare providers
- Germany dominated the antibody drug conjugates (ADC) market with the largest revenue share of 30.4% in 2024, attributed to its strong pharmaceutical industry, high healthcare expenditure, and active participation in clinical trials, with leading biopharma companies and research institutions accelerating ADC development and commercialization
- France is expected to be the fastest growing country in the antibody drug conjugates (ADC) market during the forecast period due to expanding oncology research programs, favorable reimbursement policies, and increased patient access to innovative cancer therapies
- The breast cancer segment led the antibody drug conjugates (ADC) market with a market share of 39.5% in 2024, driven by high disease prevalence and the success of approved ADCs such as trastuzumab deruxtecan in addressing HER2-positive and HER2-low subtypes
